{"title":"[Effect of Muxiang Shunqi Pill on Digestive Disorders of Prephase Uremia Patients and Its Mechanism].","authors":"Wei Cai, Wen-Li Chen, Hui-Ling Fu","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Objective To observe the effect of Muxiang Shunqi Pill (MSP) on digestive disorders of prephase uremia patients, and to study its underlying mechanism. Methods A total of 40 prephase uremia patients with gastrointestinal symptoms were randomly and equally assigned to the MSP group and the Mosapride group. Besides, 20 subjects with normal physical examinations were recruited as the control. Patients in the MSP group took MSP, 6 g each time, three times per day, taken 30 min after dinner. Those in the Mosaprido group took Mosapride Tablet (MT) , 5 mg each time, three times per day, taken 30 min before diner. The therapeutic course for all was 4 weeks. The clinical curative effect was observed. Electrogastrogram, serum levels of gastrin (GAS) and motilin (MTL) , safety and recurrence rate were evaluated. Results The total effective rate was 90% (18/20) and the recurrence rate was 15% (320) in the MSP group, higher than those of the Mosapride group [60%(12/20) , X² =4. 80, P =0. 025; 45% (9/20) , X² =4. 29, P =0. 025]. Compared with before treatment in the same group, the percentage of normal rhythm increased, the bradygastria rate was lowered, serum levels of GAS and MTL increased in the two groups after treatment (P <0. 05, P <0. 01). Compared with the Mosapride group, the bradygastria rate decreased more obviously, serum levels of GAS and MTL were increased more in the MSP group (P <0. 05, P <0. 01). Conclusion MSP could effectively improve digestive disorders of prephase uremia patients, which might be achieved through promoting gastrointestinal motility and regulating ser- um levels of gastrointestinal hormones.</p>","PeriodicalId":10107,"journal":{"name":"中国中西医结合杂志","volume":"37 1","pages":"34-38"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国中西医结合杂志","FirstCategoryId":"3","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective To observe the effect of Muxiang Shunqi Pill (MSP) on digestive disorders of prephase uremia patients, and to study its underlying mechanism. Methods A total of 40 prephase uremia patients with gastrointestinal symptoms were randomly and equally assigned to the MSP group and the Mosapride group. Besides, 20 subjects with normal physical examinations were recruited as the control. Patients in the MSP group took MSP, 6 g each time, three times per day, taken 30 min after dinner. Those in the Mosaprido group took Mosapride Tablet (MT) , 5 mg each time, three times per day, taken 30 min before diner. The therapeutic course for all was 4 weeks. The clinical curative effect was observed. Electrogastrogram, serum levels of gastrin (GAS) and motilin (MTL) , safety and recurrence rate were evaluated. Results The total effective rate was 90% (18/20) and the recurrence rate was 15% (320) in the MSP group, higher than those of the Mosapride group [60%(12/20) , X² =4. 80, P =0. 025; 45% (9/20) , X² =4. 29, P =0. 025]. Compared with before treatment in the same group, the percentage of normal rhythm increased, the bradygastria rate was lowered, serum levels of GAS and MTL increased in the two groups after treatment (P <0. 05, P <0. 01). Compared with the Mosapride group, the bradygastria rate decreased more obviously, serum levels of GAS and MTL were increased more in the MSP group (P <0. 05, P <0. 01). Conclusion MSP could effectively improve digestive disorders of prephase uremia patients, which might be achieved through promoting gastrointestinal motility and regulating ser- um levels of gastrointestinal hormones.
目的观察木香顺气丸对尿毒症前期患者消化功能紊乱的影响,并探讨其作用机制。方法将40例有胃肠道症状的尿毒症前期患者随机分为MSP组和莫沙必利组。另外,选取体格检查正常的20名受试者作为对照。MSP组患者服用MSP,每次6 g,每日3次,餐后30分钟服用。莫沙必利组服用莫沙必利片(MT),每次5毫克,每日3次,餐前30分钟服用。疗程均为4周。观察临床疗效。评估胃电图、血清胃泌素(GAS)和胃动素(MTL)水平、安全性和复发率。结果MSP组总有效率为90%(18/20),复发率为15%(320),高于莫沙必利组的60%(12/20),X²=4。80, p =0。025;45% (9/20) x²=4。29, p =0。025]。与同组治疗前比较,治疗后两组患者心律正常百分率升高,胃脘痛发生率降低,血清GAS、MTL水平升高(P